Watch past educational presentations and see live events in real time
Reference our medication guides for helpful information
Explore available award and grant opportunities for fellows-in-training.
Make a choice that matters
The best care starts with the best information. See videos to help answer your questions.
The ACR is accepting applications for mini curriculums, which are educational activities or curriculums to enhance the ACR Core Curriculum Outline.
The ACR and EULAR are reviewing proposals for new collaborative projects in the following areas:
2021 Call for Proposals Is Open
To better streamline cross-organizational processes, the ACR and EULAR have an annual deadline for proposal submissions.
Proposals will be evaluated based on:
Proposals that fall into one of these categories will be favored:
May 10, 2021
Receipt of Declarations of Interest, project outlines and disclosure / NIH biographical sketch information will be acknowledged by reply email. By May 26, 2021, the ACR and EULAR will review the submitted Declarations of Interest and send formal invitations to investigators from whom full proposals are desired.
September 8, 2021
Full proposals are due.
September 2021 – March 2022
ACR and EULAR committees and leadership will review project proposal(s) and vote on whether to fund project(s). Applicants will be notified whether a project has been approved for funding by March 28, 2022.
Funding for projects becomes available; work begins.
Joint funding from ACR and EULAR may be approved for one to two projects. Project proposals will be judged on their merits; however, it is possible that no projects will be funded, depending on the quality of the proposals received.
Each proposal should include an itemized budget for total project funding needs. This information will be evaluated when the proposals are reviewed. The ACR will fund a maximum of $65,000 per project. EULAR support will be equal to ACR funding (i.e., equivalent amount, in Euros). EULAR funding must primarily be allocated to meeting and related travel expenses, with the balance supporting European fellows (up to €15,000) and administrative costs (up to €5,000). Indirect/overhead costs and salary support should not be included in project budgets.
Stipulations to the funding of all joint criteria/points to consider projects include but are not limited to the completion of regular progress reports submitted to the ACR and EULAR by April 15 of every year throughout the course of the project (or more often, if requested), potential for presentation during the ACR and/or EULAR Annual Scientific Meetings, and submission of a completed manuscript to either Arthritis and Rheumatology or the Annals of Rheumatic Disease, as directed by ACR and EULAR for each project, with the intention of joint publication.
A completed disclosure form must be submitted with the Declaration of Interest for each person who would be intellectually involved in the project. ALL relationships must be disclosed on this form, regardless of whether they might constitute conflict. Individuals should ensure that all financial relationships with companies that are related in any way with the disease for which criteria are being developed are included, as well as any other relationships they have. Examples include, but are not limited to, companies making drugs to treat the disease or making assays, biomarkers, or other tools used for diagnosis, prognosis or response to treatment.
The ACR and EULAR PIs must be free of conflict of interest related to the criteria proposal. In addition, no more than 49% of the project development team may have conflicts of interest related to the criteria proposal.
The proposal review process will include an evaluation of whether the PIs are free of conflict of interest and the team has less than 49% members with potential conflict of interest. Financial relationships will be examined closely by proposal reviewers to determine whether the relationship could constitute a conflict of interest. Examples of potential conflict of interest include relationship with a company making a drug known to affect a specific biomarker that might be considered in the response criteria (e.g., anti-IL6 effect on CRP); or a company making an assay or biomarker or other testing modality used to diagnose the disease (in the case of classification criteria) or used to assess response to treatment (in the case of response criteria). In addition, the proposed project group will be examined for balance to ensure that various viewpoints are represented, and the final product is not likely to be biased because of potential conflicts within the group.
Please submit your Declaration of Interest, project outline, disclosures and CVs by May 10, 2021, and your full proposal - if invited by the ACR and EULAR - by September 8, 2021, to Regina Parker at email@example.com.
If you have any questions regarding your submission, please contact Regina Parker at firstname.lastname@example.org or 404-633-3777, ext. 822.